文献速递脊柱关节炎

戈利木单抗联合甲氨蝶呤与甲氨蝶呤治疗早期未治疗银屑病关节炎的随机对照试验

Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.
PubMed 文献 · Lancet Rheumatol · 2025-09-03

这项单中心双盲随机对照试验纳入84例早期未治疗的活动性银屑病关节炎患者,比较戈利木单抗联合甲氨蝶呤与安慰剂联合甲氨蝶呤(均加用糖皮质激素)的疗效。第24周时两组PASDAS无统计学显著差异(校正差值-0.55,95%CI -1.12至0.03;p=0.064),但安慰剂联合甲氨蝶呤组需要额外糖皮质激素的比例更高。两组均无死亡、严重或意外不良事件。

要点

  • 第24周PASDAS两组无统计学显著差异(校正差值-0.55,95%CI -1.12至0.03;p=0.064)。
  • 安慰剂联合甲氨蝶呤组更多患者在第24周前接受额外糖皮质激素(49% vs 21%;OR 0.28,95%CI 0.11至0.72;p=0.009)。
  • 两组不良事件数量相似,但戈利木单抗联合甲氨蝶呤组实验室检查异常和感染更常见。

核心结论

  • 两种干预均改善早期未治疗银屑病关节炎患者的疾病活动度,第24周两组PASDAS无临床或统计学显著差异。
  • 安慰剂联合甲氨蝶呤组需要更多补救糖皮质激素,第52周两组持续观察到结果且无严重或意外不良事件。

研究设计与样本

  • 单中心、双盲、随机、安慰剂对照、平行组研究,纳入成人未治疗的活动性银屑病关节炎患者,诊断至入组不超过24个月,且未使用过传统合成、生物或靶向合成改善病情抗风湿药或全身治疗。
  • 参与者按1:1随机分配至戈利木单抗联合甲氨蝶呤组(43例)或安慰剂联合甲氨蝶呤组(41例),按基线受累外周关节数分层。
  • 基线时所有参与者接受甲泼尼龙120 mg单次肌内注射,并开始每周甲氨蝶呤(28天内增至25 mg);戈利木单抗或安慰剂每4周皮下注射;第24周前允许额外一次甲泼尼龙(总暴露至多240 mg)。
  • 主要终点为意向治疗人群第24周PASDAS均值差异,采用协方差分析经多元线性回归比较。
  • 研究在EudraCT注册(2013-004122-28),已完成;2015年11月3日至2022年1月26日期间评估106人资格,排除22人,随机分配84人。

主要发现

  • 第24周PASDAS:安慰剂联合甲氨蝶呤组未校正均值3.09(SD 1.32),戈利木单抗联合甲氨蝶呤组2.70(SD 1.38);校正差值-0.55(95%CI -1.12至0.03);p=0.064。
  • 第24周前接受额外糖皮质激素:安慰剂联合甲氨蝶呤组20/41(49%),戈利木单抗联合甲氨蝶呤组9/43(21%);OR 0.28(95%CI 0.11至0.72);p=0.009。
  • 不良事件:安慰剂联合甲氨蝶呤组38/41(93%),戈利木单抗联合甲氨蝶呤组41/43(95%);风险差0.03(95%CI -0.09至0.15);戈利木单抗联合甲氨蝶呤组实验室检查异常和感染更常见。
  • 无死亡、严重或意外不良事件发生;第52周两组持续观察到结果。
  • 人口学:46例(55%)男性,38例(45%)女性;平均年龄42.5岁(SD 12.4);61例(73%)白人,7例(8%)来自亚洲、黑人或其他族裔背景。

临床怎么用

  • 原文结论指出两种干预均改善早期未治疗银屑病关节炎的疾病活动度,第24周PASDAS组间无临床或统计学显著差异,安慰剂联合甲氨蝶呤组需要更多补救糖皮质激素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal treatment strategy in early psoriatic arthritis remains unknown. We aimed to assess whether the combination of methotrexate and golimumab plus corticosteroids is superior to methotrexate plus corticosteroids in reducing disease activity in early, untreated psoriatic arthritis. METHODS: We did a double-blind, randomised, placebo-controlled, parallel-group, single-centre study in adults with treatment-naïve active psoriatic arthritis. Participants were required to have been diagnosed up to 24 months before enrolment and had to be naïve to conventional synthetic, biologic, or targeted synthetic disease-modifying antirheumatic drugs or systemic treatments before enrolment. Participants were randomly assigned (1:1) to receive either combination therapy of golimumab and methotrexate or placebo and methotrexate, stratified by the number of involved peripheral joints at baseline. Investigators and participants were masked to treatment allocation. At baseline, all participants received methylprednisolone (120 mg intramuscular administration, single dose) and commenced weekly methotrexate (increased to 25 mg within 28 days). Golimumab or placebo were administered by subcutaneous injections every 4 weeks. By week 24, additional methylprednisolone was permitted once (totalling up to 240 mg exposure). The primary endpoint was the difference in mean Psoriatic Arthritis Disease Activity Score (PASDAS) at week 24 in the intention-to-treat population, compared using analysis of covariance via multiple linear regression. People with lived experience of psoriatic arthritis were involved in the design and conduct the study. The study was registered with EudraCT, 2013-004122-28, and is complete. FINDINGS: Between Nov 3, 2015 and Jan 26, 2022, 106 people were assessed for eligibility, 22 were excluded, and 84 were randomly assigned (43 to the golimumab and methotrexate group and 41 to the placebo and methotrexate group). 46 (55%) participants were male and 38 (45%) were female. The mean age was 42·5 years (SD 12·4) and 61 (73%) participants were White and seven (8%) were from any Asian, Black, or other ethnic background. PASDAS did not differ between treatment groups at week 24 (unadjusted mean 3·09 [SD 1·32] in the placebo and methotrexate group and 2·70 [1·38] in the golimumab and methotrexate group; adjusted difference -0·55 [95% CI -1·12 to 0·03]; p=0·064). More participants in the placebo and methotrexate group received additional corticosteroids before week 24 (20 [49%] of 41 vs nine [21%] of 43; odds ratio 0·28 [95% CI 0·11 to 0·72]; p=0·009). Similar numbers of participants had adverse events (38 [93%] of 41 in the placebo and methotrexate group vs 41 [95%] of 43 in the golimumab and methotrexate group; risk difference 0·03 [95% CI -0·09 to 0·15]), although altered laboratory investigations and infections occurred more frequently in the golimumab and methotrexate group. No deaths, serious, or unexpected adverse events occurred. INTERPRETATION: Both interventions led to improved disease activity in patients with early, untreated psoriatic arthritis, without a clinically or statistically significant difference in PASDAS between treatment groups at week 24. Participants in the placebo and methotrexate group required more rescue corticosteroids. Sustained results were observed at week 52 in both groups, without serious or unexpected adverse events. FUNDING: Janssen Biologics BV.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. De Marco G, Hensor EMA, Helliwell PS, et al. Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial. Lancet Rheumatol. 2025. PMID: 40914172. doi:10.1016/S2665-9913(25)00156-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。